Cytek Biosciences (NASDAQ:CTKB) Preliminary Full Year 2024 Revenue Results AnnouncedOn January 15, 2025, Cytek Biosciences, Inc. released its preliminary unaudited revenue for the fourth quarter and full year that concluded on December 31, 2024. The

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cytek Biosciences’s 8K filing here.

About Cytek Biosciences

(Get Free Report)

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.

See Also